BioSpace News Archive

Positive Phase 3 Study Results for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation -Phase 3 study met primary endpoint and all secondary endpoints- -Study is a U.S. post-marketing commitment and will be submitted to FDA- -Data also will be submitted to the European Medicines Agency to support indic

PerkinElmer Introduces AuroFlow ® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities Features water-based testing strips and handheld reader delivering convenience and accuracy

Biodesix, Inc. a leader in lung cancer diagnostics, announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors.

Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced it has received the U.S. Food and Drug Administration 510 clearance and European CE Mark approval for the JuniOrtho® Plating System.

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator),

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., the Chairman of Rhythm’s Board of Directors, has been appointed as the President and Chief Executive Officer (CEO) of the company, effective immediately. Dr. Meeker succeeds Hunter Smith, the Company’s Interim President and CE

BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the “Company”), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Alex Monteith as Senior Vice President and Ch

Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced the appointments of Ms. Priyanka Misra as Vice President of Corporate Development and Dr. Elise Brownell as Vice President of Research & Developmen

Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease